Manuel Fernández-Sánchez is the director of IVI Sevilla, Associate Professor of Assisted Reproductive Technology and Gene Therapy in Molecular Biology and Biochemical Engineering in Department, Pablo Olavide University, Sevilla, and Associate Professor of Biomedicine and Gynecology in Faculty of Medicine, University of Sevilla. Dr. Fernandez-Sanchez, trained at CHI Andre Gregoire Hospital of Paris (France), and The Queen’s Medical Research Institute in Edinburgh (the United Kingdom). He also obtained a Degree of Statistics and Research Methodology at the University Autónoma of Barcelona, he completed a Master of Human Reproduction at University Rey Juan Carlos of Madrid and an Executive Master in Management and Administration of Health Institutions in Esade Business School, Ramon Llul University, Madrid.
He holds a Ph.D. in medicine from the University of Valencia. He has published research articles in leading international reproductive journals and received four Seville Medical Society Awards and two Royal Medicine Academy of Seville Awards. He was the National Coordinator of Embryo Health Task Force of Spanish Fertility Society for 4 years. He is an elected Member of the Royal Academy of Medicine Seville.
|MD||University of Sevilla (1996)|
|Residency||University of Seville (2002)|
|Fellowship||CHI Andre Gregoire Hospital of Paris (2002)|
|M.Sc. in Statistics and Research Methodology||Autonomous University of Barcelona (2008)|
|Fellowship||The Queen’s Medical Research Institute in Edinburgh (2009)|
|MSc in Human Reproduction||Rey Juan Carlos University of Madrid (2009)|
|Ph.D.||University of Valencia (2012)|
|M.Sc. in Management and Administration of Health Institutions||Ramón Llull University (2015)|
Honores y reconocimientos
|Illustrious doctor by the Royal Medicine Academy of Seville||2015|
|1st Award of the Royal Medicine Academy of Seville||2008|
|1st Award of the Royal Medicine Academy of Seville||2006|
|3rd Merck-Serono Award, Salud 2000 Foundation. Clinical investigation Area||2006|
|1st Scientific Award of the Seville Medical Society||2006|
Deregulation of miR-324/Kiss1/kisspeptin in early ectopic pregnancy: Mechanistic findings with clinical and diagnostic implications.
Romero-Ruiz A Avendaño MS Dominguez F Lozoya T Molina-Abril H Sangiao-Alvarellos S Gurrea M Lara-Chica M Fernandez-Sanchez M Torres E Perdices-Lopez C Abbara A Steffani L Calzado MA Dhillo WS Pellicer A Tena-Sempere M
Am J Obstet Gynecol. 2019 Jan 29. pii: S0002-9378(19)30282-0. doi: 10.1016/j.ajog.2019.01.228. [Epub ahead of print
- Simon C Gómez C Cabanillas S Vladimirov IK Castillón G Giles J Boynukalin FK Findikli N Ortega I Vidal C Izquierdo A Portela S Frantz N Taguchi S Labarta E Colucci F Mackens S Santamaría X Muñoz E Barrera SG Fernandez-Sanchez M O-134 IN VITRO FERTILIZATION WITH PERSONALIZED BLASTOCYST TRANSFER VERSUS FROZEN OR FRESH BLASTOCYST TRANSFER: A MULTICENTER, RANDOMIZED CLINICAL TRIAL. Presented at the 35th annual meeting of the European Society of Human Reproduction and Embryology, Vienna, Austria, 14-16 October 2019
- Fernandez-Sanchez M Visnova H Yuzpe A Klein BM Mannaerts B Arce JC Individualization of the starting dose of gonadotropin reduces the overall ohss risk and the need of preventive cumulative data over three. Presented at the 34rd annual meeting of the European Society of Human Reproduction and Embryology, Barcelona, Spain, October 6-10, 2018
- González-Ravina C Cruz M Rubio C Fernández-Sánchez M Oquiñena E Ferrando R Requena A Polymorphic chromosome variants, human inversions, and their functional consequences in male infertility. , , July 2-5 ,2017
- Rubio Lluesa C Cruz M González-Ravina C Fernández-Sánchez M Oquiñena E Requena A Polymorphism on chromosome 21 does not affect ovarian reserve but clinical outcomes after in vitro fertilization treatments. , , July 2-5 ,2017